fashion -WSS

fashion

author：entertainment 2025-10-04 04:01:46 - browse：8

A heart monitoring watch, referred as Project Zero 2.0 is displayed in the Omron Healthcare booth during a press event – health tech coverage from STAT — Digital tools to better track blood pressure over time and encourage adherence to treatment plans are increasingly commonplace. David Becker/Getty Images

If you have high blood pressure, it’s increasingly likely that your doctor or your insurer will offer you a blood pressure cuff or an educational app to help you get it under control. While potentially impactful, these tools may not be reaching marginalized people who don’t regularly have access to good health care — and who may benefit the most from the tools.

A new analysis suggests that there ought to be more investment in novel hypertension programs for people experiencing health disparities.The meta-review of 28 studies of digital health interventions for people of color and low-income patients found that as a whole participants saw a statistically significant and clinically meaningful reduction in average systolic blood pressure compared to control groups. In total, the analysis included more than 8,000 participants; most of the studies followed participants for six or 12 months. The results, published Wednesday in JAMA Network Open, are consistent with studies of digital tools in the general population.

Joseph Ebinger, of the Smidt Heart Institute at Cedars-Sinai in Los Angeles, who was not involved in the study, said it provides needed evidence that “there are tools that exist to be able to help meet individuals where they are in the world, and they should be utilized more heavily.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The Readout: Amylyx, Alumis, and Lundbeck drug updates

WSS

Humana cuts profit projections as Medicare Advantage costs soar

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Amylyx ALS drug fails large clinical trial

UnitedHealth quietly bought dozens of outpatient centers

CDC marks new Covid

explore

fashion

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Anesthesiologist group: stop taking Ozempic before surgery

New brain studies show LSD's effects on the brain in full color

Cancer drug shortages should be causing more outrage

RSV shot was 90% effective at preventing hospitalizations in kids

BioMarin wins approval for gene therapy to treat hemophilia A

Research misconduct: Proposed new rules face resistance

Dobbs anniversary: the lost opportunity of abortion as health care

FDA clears AI tool for detecting skin cancer

knowledge

NIH director takes cautious approach to Biden drug pricing priority

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

What it’s like to watch children die of measles

My yearlong odyssey to get my son’s ADHD medication covered

Copay coupons to count toward deductibles, after Biden court move

The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

knowledge

entertainment

explore